Description
Product Usage Information
This product is the carrier-free version of product #19541. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN, or CUT&Tag assays. If you require a carrier-free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity.
Formulation
Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 19541 .
Storage
Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.
Specificity / Sensitivity
4-1BB/CD137/TNFRSF9 (E6Z7F) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total 4-1BB/CD137/TNFRSF9 protein.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein corresponding to the extracellular domain of human 4-1BB/CD137/TNFRSF9 protein.
Background
TNFRSF9 is a member of the tumor necrosis factor receptor superfamily (1,2). It is also called 4-1BB or CD137 (1, 2). 4-1BB/CD137/TNFRSF9 is expressed in activated CD4+ and CD8+ T cells, natural killer cells and dendritic cells (2-5). The ligand 4-1BBL/CD137L/TNFSF9 on antigen presenting cells binds to 4-1BB/CD137/TNFRSF9 and costimulates the activation of T cells (5). The binding of agonistic antibodies to 4-1BB/CD137/TNFRSF9 also leads to costimulation for T cell activation (5). Studies have shown the effectiveness of targeting 4-1BB/CD137/TNFRSF9 by its agonistic antibodies in cancer immunotherapy (6).
Alternate Names
4-1BB; 4-1BB ligand receptor; CD137; CD137 antigen; CDw137; homolog of mouse 4-1BB; ILA; induced by lymphocyte activation (ILA); interleukin-activated receptor, homolog of mouse Ly63; MGC2172; receptor protein 4-1BB; T cell antigen ILA; T-cell antigen 4-1BB homolog; T-cell antigen ILA; TNF receptor superfamily member 9; TNFRSF9; TNR9; Tumor necrosis factor receptor superfamily member 9; tumor necrosis factor receptor superfamily, member 9
